Research Article
Cognitive Function in Parkinson’s Disease Patients with and without Anxiety
Table 1
Demographic and clinical variables in PD participants.
| | Variable | PDA−
() | PDA+
() | values |
| | Demographic | | | | | Age (years) | 68.3 (8.9) | 64.9 (8.1) | | | Gender (% male) | 19/14 (57.6%) | 9/8 (52.9%) | | | Clinical | | | | | Disease duration (years) | 6.6 (4.2) | 6.6 (5.6) | | | UPDRS-III | 31.9 (13.0) | 31.2 (15.3) | | | LPD/RPD ratio (% LPD) | 15/17 (45.5%) | 6/11 (35.3%) | | | H&Y stage, median (range) | 2.0 (1–4) | 2.0 (1–5) | | | LEDD, mg/day | 674.0 (550.5) | 710.2 (478.7) | | | HADS-A | 2.03 (1.6) | 10.5 (1.9) | | | HADS-D | 3.2 (1.7) | 4.1 (1.6) | | | HADS-total | 5.2 (2.7) | 14.7 (2.9) | |
|
|
Note: values reflect mean (SD). LEDD: levodopa equivalent daily dose. indicates significant group differences.
|
